Coexistence of familial mediterranean fever and juvenile idiopathic arthritis with osteoporosis successfully treated with etanercept

Internal Medicine

Volumn 49, Issue 6, 2010, Pages 619-622

  Kaya, Sunay ^a   Kaptanoglu, Ece ^a   Elden, Hasan ^a   Hizmetli, Sami ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Etanercept; FMF; JIA; Osteoporosis

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; COLCHICINE; CORTICOSTEROID; DEXAMETHASONE; ETANERCEPT; FOLIC ACID; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; RISEDRONIC ACID; VITAMIN D;

ADULT; ARTICLE; BONE EROSION; CARPAL BONE; CASE REPORT; CHROMOSOME 16; DRUG DOSE REDUCTION; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL MEDITERRANEAN FEVER; FOLLOW UP; GENE LOCATION; GENE MUTATION; GENETIC ANALYSIS; HAND MALFORMATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MALE; METACARPOPHALANGEAL JOINT; OSTEOPOROSIS; PROTEINURIA; RANGE OF MOTION; THROMBOCYTE COUNT; URINALYSIS;

ADULT; ARTHRITIS, JUVENILE RHEUMATOID; COMORBIDITY; FAMILIAL MEDITERRANEAN FEVER; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; OSTEOPOROSIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 77950636944     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.2777     Document Type: Article

References (16)

1. Bhat A, Naguwa SM, Gershwin ME. Genetics and new treatment modalities for familial Mediterranean fever. Ann NY Acad Sci 1110: 201-208, 2007
2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 369: 767-778, 2007.
3. Rozenbaum M, Rosner I. Severe outcome of juvenile idiopathic arthritis associated with FMF. Clin Exp Reumatol 22: s75-s78, 2004.
4. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40: 1879-1885, 1997.
5. Rabinovich E, Livneh A, Langevitz P, et al. Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene. Ann Rheum Dis 64: 1009-1014, 2005.
6. Ayaz NA, Ozen S, Bilginer Y, et al. MEFV mutations in systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 48: 23-25, 2009.
7. El-Shanti H, Majeed HA, El-Khateeb M. Familial Mediterranean fever in Arabs. Lancet 367: 1016-1024, 2006.
8. Lidar M, Livneh A. Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med 65: 318-324, 2007.
9. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2009 Oct 22 [Epub ahead of print].
10. Baykal Y, Saglam K, Yilmaz MI, Taslipinar A, Akinci SB, Inal A. Serum sIL2, IL-6, IL-10 and TNF-α in familial Mediterranean fever patients. Clin Rheumatol 22: 99-101, 2003.
11. Ozgocmen S, Ozcakar L, Ardicoglu O, Karakoc E, Kaya A, Kiris A. Familial Mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol 25: 83-87, 2005.
12. Daysal S, Akcil G, Goker B, Haznedaroglu S, Ercan N, Ozturk MA. Inflximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum 53: 146-148, 2005.
13. Yuksel S, Yalcinkaya F, Acar B, Ozcakar ZB, Ozturk B, Ekim M. Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford) 45: 1307-1321, 2006.
14. Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol 10: 134-137, 2004.
15. Mor A, Pillinger MH, Kishimoto M, Abeles AM, Livneh A. Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol 13: 38-40, 2007.
16. McMahon MS, Ueki Y. Does anti-TNF alpha have a role in the treatment of osteoporosis? Bulletin of the NYU Hospital for Joint Diseases 66: 280-281, 2008.